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SERPING1 mutations causing Hereditary Angioedema type I (HAE-I) due to C1-Inhibitor (C1-INH) deficiency display a
dominant-negative effect usually resulting in protein levels far below the expected 50%. To further investigate
mechanisms for its reduced expression, we analyzed the promoter DNA methylation status of SERPING1 and its
influence on C1-INH expression. Global epigenetic reactivation correlated with C1-INH mRNA synthesis and protein
secretion in Huh7 hepatoma cells. However, PBMCs extracted from controls, HAE-I and HAE-II patients presented
identical methylation status of the SERPING1 promoter when analyzed by bisulphite sequencing; the proximal CpG
island (exon 2) is constitutively unmethylated, while the most distant one (5.7 Kb upstream the transcriptional start
site) is fully methylated. These results correlate with the methylation profile observed in Huh7 cells and indicate that
there is not a direct epigenetic regulation of C1-INH expression in PBMCs specific for each HAE type. Other indirect
modes of epigenetic regulation cannot be excluded.
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C1-Inhibitor (C1-INH; OMIM#606860) is a SERPIN regu-
lating the activation of the classical and lectin complement
pathways, coagulation and fibrinolysis cascades [1]. It is
mainly produced in the liver, although local synthesis by
monocytes, fibroblasts and endothelial cells in inflamma-
tory foci also exists. Deficiency of C1-INH due to mutations
in the SERPING1 gene causes Hereditary Angioedema
(HAE) types I and II. HAE type I (HAE-I) can be due to
mutations located throughout the gene sequence and is
characterized by functional and antigenic C1-INH defi-
ciency. HAE type II (HAE-II) is caused by point mutations* Correspondence: mltrascasa@salud.madrid.org
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article, unless otherwise stated.affecting the reactive centre of the protein or nearby resi-
dues and presents with reduced function but normal anti-
genic levels of the protein. HAE patients suffer from
recurrent disabling episodes of swelling in the subcutane-
ous and submucosal layers which can affect any body lo-
cation and, if not promptly and properly treated, can lead
to suffocation when the larynx is affected [2].
HAE is inherited in an autosomal dominant manner.
Typically, HAE-I heterozygous patients exhibit C1-INH
levels that are markedly below the expected 50% of con-
trols, while type II patients have normal levels, but reduced
function of C1-INH. Thus, regarding protein levels, HAE-I
mutant alleles seem to exert dominant negative effects on
their wild-type counterparts, rendering similarly reduced
mRNA levels in both alleles to around 50% [3-5]. Add-
itionally, a small percentage of HAE patients exhibiting
reduced C1-INH function do not carry known SERPING1tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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MLPA screening; therefore, alternative modes of regulating
C1-INH remain to be identified.
DNA methylation is an epigenetic event that plays a
role in development, aging, chromatin structure, gen-
omic imprinting and gene and microRNA expression.
Altered DNA methylation patterns have been described
in many genes and microRNAs associated with disease
[6-8], including some members of the SERPIN super-
family, whose epigenetic alterations have been described
in human placental diseases [9]. To contribute to the
understanding of C1-INH's regulation of expression in
HAE, we have investigated the CpG methylation status
of the C1-INH locus and its surrounding regions in the
hepatoma cell line Huh7 and in stored DNA samples
from PBMCs obtained from healthy donors, HAE-I and
HAE-II patients.Figure 1 Re-expression studies. (A) Schema of the SERPING1 locus indica
extends over exon 2 and comprises also part of the contiguous introns 1 and
demethylation induced by 5-Aza-2′-deoxycytidine (5’Aza) and Trichostatin A (
carcinoma cells more effectively than IFN-γ treatment (C) resulting in an increa
by western blot analyses with both anti-C1-INH mAbs and biotinylated C1s. Re
amounts of mRNA extracted from unstimulated Huh7 cultures as reference.Results and disussion
Identification of putative CpG islands in the SERPING1 locus
The screening for CpG islands was initially performed in
the SERPING1’s genomic region containing its coding se-
quences (exons 1 to 8 and their adjacent introns). Next,
we extended the search 6 kb in 5’ direction until the clos-
est CpG cluster addressing the selection criteria:
More than 55% of GC dinucleotides (i), ObservedCpG
vs. Expected CpG ratio: 0.65 (ii), Length: at least 200 bp
(iii), Distance: 100 bp (iv).
Two relaxed CpG islands endorsed by literature [9] were
identified in the 11q11-q13.1 region according to the CpG
Island Searcher software (http://cpgislands.usc.edu/) [10]
(Figure 1A). The nearest CpG island to the ATG site (re-
ferred to as CpG island 1 or 3' island) comprises the
73 bp-exon 2 of the SERPING1 gene and its surrounding
intronic regions, 58 bp upstream and 224 bp downstreamting the positions of the most proximal CpG islands. CpG island 1
2, while CpG island 2 is located 5740 bp upstream exon 1. (B) Global
TSA), upregulates SERPING1 mRNA expression in Huh7 hepatocellular
sed C1-INH protein expression in Huh7 culture supernatants, as indicated
lative quantification of SERPING1 expression was performed using equal
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of CpG dinucleotides. The second CpG island - termed
CpG island 2 or 5' island- is located between 5940 and
5740 bp upstream of the gene's first exon. It contains 59%
CpGs and spans 200 bp.
Global demethylation induced by 5’Aza and TSA
upregulates SERPING1 expression in Huh7 cells at the
mRNA and protein levels
To our knowledge, no studies focused on quantifying
C1-INH synthesis in Huh7 cells have been published, but
the matter has been extensively addressed in other hepa-
tocellular carcinoma cell lines, especially in the HepG2
line. HepG2 cells synthesize and secrete functional C1-
INH and its expression is enhanced by IFN-γ administra-
tion in a dose-dependent manner [11,12].
We quantified C1-INH mRNA from 1 μg of total RNA
extracted from 75% confluent Huh-7 control cell culturesFigure 2 Bisulphite sequencing. Chromatograms showing the results of
and 2 (left and right panels, respectively), (B) Sequence of the bisulphite-m
panels, respectively) and (C) CpG island 2 type I and type II HAE patients (le
susceptible of methylation. Wild Type sequences are: CpG Island 1: tgggctccc
2: tggaggcCGaggCGggtggatcaCGaggtcaggagatCGagacccatcctggctaacaCG.and compared it to that of Huh7 cells treated with
5’Aza + TSA for 3 culture days as described [13]. Reverse-
transcription with oligo-dT primers (Qiagen, Valencia, CA)
and quantification using a SYBR Green system (Applied
Biosystems, Foster City, CA) were performed as previously
described [14].
Similarly to what is seen in IFN-γ treated cells, global de-
methylation strongly correlated with enhanced SERPING1
mRNA synthesis. Furthermore, mRNA synthesis was
higher in 5’Aza + TSA-treated cultures (38-fold) than in
those exposed to 250UI/mL of IFN-γ for 3 days (20-fold).
Combined addition of 5Aza, TSA and IFN-γ during 3
culture days produced a non-additive effect resulting in a
28-fold change upregulation of SERPING1 expression
(Figure 1B). This probably reflects the consequences of glo-
bal DNA/histones demethylation on the transcriptional/
translational regulation of the IFNG gene (encoding human
IFN-γ) or other loci involved in the transduction of IFN-γbisulphite sequencing in: (A) Huh7 hepatoma cells in CpG islands 1
odified CpG island 1 in type I and type II HAE patients (left and right
ft and right panels, respectively) (C). Arrows indicate the CpG positions
agggtgggagCtggctcCGaggctggctggctcCGcaggtcCGctgaCG. CpG Island
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are known to play a role in transcriptional activation and
silencing of IFN-γ signalling [15].
C1-INH protein presents two different isoforms in
serum and plasma by western blot analysis: a 105 KDa
protein representing its native, non-cleaved conform-
ation and an additional 96 kDa form corresponding to
its cleaved, latent, non-functional conformation. In our
hands, Huh7 cultures exhibit a single 105 kDa native
band, which suggests the absence of activity involving
those serum proteolytic pathways regulated by C1-INH
(Figure 1C). Western blot analysis of culture superna-
tants confirmed SERPING1 synthesis observed at the
RNA level; no bands were observed in the supernatants
of control Huh7 cells after three days of culture, while a
single 105 kDa band corresponding to the native conform-
ation of C1-INH was visible in treated Huh7 cells both by
monoclonal anti-C1-INH antibody and biotinylated-C1s'
detection systems (Figure 1C). Those results indicate
a possible epigenetic regulation of SERPING1 gene ex-
pression in the Huh7 hepatoma cells.
CpG island 1 is unmethylated in HAE patients and
controls while CpG island 2 is methylated
Bisulphite sequencing of stored genomic DNA samples
obtained from HAE PBMCs (8 type I and 8 type II,
Additional file 1), 10 healthy donor PBMCs and Huh7
cells was carried out as previously described [16] These
studies received approval from the ethical committee of
Hospital La Paz.
We included genomic DNAs from a homozygous-
deficient patient carrying the R378C missense mutation
in exon 7 and a heterozygous relative (samples 3 and 3b,
respectively). Genetic and biochemical characterization
of these patients has been previously described [17]. The
T157fsX78 frameshift mutation in HAE-I patients 4, 4b
and 4c and the exon 4 deletion in patients 1 and 6 are
expected to profoundly reduce SERPING1 mRNA levels
due to the introduction of premature stop codons. In
contrast, the remaining type I and type II mutations do
not have obvious implications on translation or protein
structure.
Sequencing results showed that in all cases the prox-
imal CpG island 1 is unmethylated while the distal CpG
island 2 is fully methylated (Figure 2). There is no differ-
ence between Huh7 cells, control PBMCs and those ob-
tained from either HAE-I or HAE-II patients regarding
the methylation status of both CpG islands 1 and 2 ana-
lyzed in this manuscript, indicating that there is no direct
epigenetic regulation at DNA level. Therefore, transcrip-
tional regulation of the SERPING1 gene in pathological
situations like HAE is not dependent on the methylation
status of the analysed CpG islands. This epigenetic
pattern is in agreement with that reported by Chelbiand collaborators in normal and preeclampsic placentas
[9] and it is also concordant with repository data on
DNase-I treatment and transcription factor binding site ac-
cessibility in the region, which shows a peak for DNase-
I sensitivity centred in SERPING1's exon 2 that matches
CpG island 1 [18].
Considering the lack of evidence for differential epi-
genetic regulation at the DNA methylation level of pro-
moter activity in the SERPING1 locus in HAE patients’
PBMCs, the fact that the demethylating agents 5'Aza-dC
and TSA strongly increased mRNA and protein synthesis
in Huh7 cells could reflect an upstream indirect epigenetic
regulation of trans-acting factors like transcription factors
or microRNAs in the hepatocyte. Those elements could be
reactivated by demethylation as has been reported in previ-
ous studies using similar experimental epigenetic reactiva-
tion approaches [13,19]. On the other hand, we found no
evidence for epigenetic mechanisms involving promoter
CpG islands 1 and 2 playing a starring role in the negative
dominance previously reported in HAE-I PBMCs.
The approach employed in this paper for the analysis of
SERPING1 epigenetics is evidently hindered by the impos-
sibility of obtaining hepatocyte samples from patients and
controls in which to perform re-expression studies and
bisulphite sequencing. Moreover, taking into consideration
that monocytes do not undergo cell division, they are not
suitable for 5’AZA+TSA re-expression studies, as a mini-
mum of two cell divisions are required to completely re-
move epigenetic marks from DNA and histones. Therefore,
these results are strictly limited to PBMCs and do not in-
form about epigenetic regulation in the hepatocyte, which
is the main source of plasma C1-INH.
All considered, our data suggest that CpG island 1 is
in a transcriptional-permissive chromatin conformation
that would hypothetically allow the access of transcrip-
tional machinery to the gene's promoter sites in PBMCs.
The upregulating effect of demethylating agents on Huh7
cells would be due to epigenetic regulation of additional
factors involved in SERPING1's control of transcription
and suggests an analogous mechanism could account for
the differential C1-INH plasma levels characteristic of
each HAE type.Additional file
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